KAT2A/KAT2B PROTAC Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for treatments that target the degradation of KAT2A and KAT2B proteins, which are implicated in various diseases including cancer and inflammatory conditions, as existing therapies have limitations in effectively modulating their activity.
Innovation Solution
Development of compounds that utilize the ubiquitin-proteasome system through PROTACs to specifically degrade KAT2A and KAT2B by conjugating an E3 ubiquitin ligase binding moiety to a ligand targeting these proteins, leveraging the proteasome system for targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to modulate KAT2A and KAT2B activity, then treatment options are available, but the effectiveness is limited
Solution Approach 1:
The patent employs PROTAC molecules as intermediary compounds that mediate between the target proteins (KAT2A/KAT2B) and the ubiquitin-proteasome degradation system. These bifunctional molecules contain one part that binds to the target protein and another part that recruits E3 ubiquitin ligase, facilitating targeted protein degradation without directly inhibiting the target's active site, thereby overcoming limitations of conventional therapies
2Reliability
If PROTAC compounds are developed to target KAT2A and KAT2B degradation, then therapeutic effectiveness is improved, but the complexity of the compounds increases
Solution Approach 1:
The PROTAC compounds are segmented into distinct functional modules: a target-binding ligand portion, a linker region, and an E3 ligase-binding portion. This segmentation allows each component to perform its specific function independently while being connected in a unified molecule, enabling systematic optimization of each segment to manage overall complexity
Solution Approach 2:
The patent utilizes universal E3 ligase binding moieties (such as VHL or CRBN binders) that can be paired with different target-specific ligands through appropriate linkers. This multi-functional design allows the same E3 recruitment module to work with various target proteins, reducing the need to develop entirely new complex structures for each target
3Reliability
If KAT2A and KAT2B protein levels are reduced through targeted degradation, then disease treatment is enhanced, but the mechanism requires utilization of the ubiquitin-proteasome system
Solution Approach 1:
The PROTAC mechanism leverages the cell's own ubiquitin-proteasome degradation system to eliminate target proteins. Rather than introducing an external degradation machinery, the compound recruits endogenous E3 ligases and utilizes the existing proteasome pathway, allowing the biological system to perform the degradation function autonomously once triggered by the PROTAC molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the levels of KAT2A and KAT2B, offering therapeutic potential for diseases mediated by these proteins, including cancer and inflammatory conditions, by disrupting their function and reducing their stability.
Implementation Method 1
Development of compounds that utilize the ubiquitin-proteasome system through PROTACs to specifically degrade KAT2A and KAT2B
Data Source
AI summary
The invention relates to compounds that target the degradation of KAT2A and KAT2B, their manufacture, pharmaceutical compositions comprising the compounds and their use as medicaments. The compounds of the invention are useful in the treatment of diseases and medical conditions associated with KAT2A and KAT2B, including, for example, cancer, autoimmune conditions, and inflammatory conditions.